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CTL recognize foreign antigens on the surface of target cells in association
with MHC molecules. Alloreactive cells, which recognize MHC alloantigens as
targets, existas a significant fraction ofthe T cell repertoire in mature individuals
and can be activated in vitro as a result of the allogeneic mixed lymphocyte
reaction. MHC antigen variants distinguishable by CTL have been used to
establish that changes in various positions of their amino acid sequence result in
simultaneous alteration of epitopes recognized by both alloreactive and MHC-
restricted CTL (1-5). In addition, some CTL show crossreactivity between class
I allodeterminants and self-class I-restricted foreign determinants (6, 7). Thus,
closely related epitopes on the MHC molecule could be involved in both allo-
recognition and MHC restriction. The existence of these crossreactions is in
contrast with the virtual absence of CTL showing crossreactivity between class I
and class II antigens. This lack ofcrossreactivity also holds at antibody level and
is a well-known fact in HLA serology.
With a few exceptions, human CTL that recognize class I antigens express the
CD8(T8) molecule on their surface, whereas those recognizing class 11 antigens
express CD4(T4) (8). Anti-CD8 and anti-CD4 antibodies can prevent conjugate
formation between target cells and their specific CTL (9-11). These observations
prompted the assumption that CD8 and CD4 are involved in the recognition of
nonpolymorphic sites on the class I and class 11 molecules, respectively (12).
However, direct evidence for the interaction of CD8 or CD4 with MHC antigens
has not been provided. A non-MHC-dependent regulatory role in T cell trig-
gering has also been suggested for CD4 and CD8 (13, 14).
The present work shows the characterization of three alloreactive CD8' CTL
clones that display simultaneous lytic ability for both HLA-B27.1+ cells and
HLA-DR2+ targets expressing certain DR2-associated Dw determinants. For
each ofthese clones, an anti-CD8 mAb inhibited class I-, but not classII-directed
killing, whereas lysis of all target cells was inhibited by an anti-CD3 antibody.
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This is, to our knowledge, the first example of CTL clones displaying dual class
I- and class II-directed alloreactivity. They were used to demonstrate a differ-
ential role of CD8 in the lytic mechanism of single clones, depending upon the
MHC antigen class being recognized.
Materials and Methods
Cell Lines.
￿
Human lymphoblastoid cell lines (LCL)' as well as the erythroid tumour
line K562 (used as an indicator of non-MHC-directed killer activity) were maintained in
RPMI 1640 medium supplemented with 2 MM L glutamine, 10% heat inactivated FCS
(Flow Laboratories, Inc., Middlesex, United Kingdom), and no antibiotics, at 37°C in a
humidified atmosphere of 5% C02 in air. All LCL used as stimulators were mycoplasma
free as assessed by seeding culture medium containing 2-4 X 106 cells in agar plates
consisting of 1 % Noble agar supplemented with PPLO broth, 1 % yeast extract (Difco
Laboratories, Inc., Detroit, MI) and 20% inactivated horse serum (Flow Laboratories,
Inc.). The plates were incubated for 16 h in air at 37 °C and for 6 d in a humidified
atmosphere of 5% C02 in N2 at 37 °C. The presence of mycoplasmas was revealed with
Dienes Stain (15). This test was routinely carried out once a month.
T Cell Cloning Procedures.
￿
Mixed lymphocyte cultures (MLC) and cloning were per-
formed according to amethod described elsewhere (16) with some modifications. In brief,
106 responder PBMC were stimulated with 5 X 104 irradiated (6,000 rad) LCL and 106
autologous PBMC as feeder cells. 10 d after stimulation, responding cells were either
harvested and used for cloning (primary cloning) or restimulated with 5 X 104 LCL fora
further period of 6d, after which the cells were harvested and used forsecondary cloning.
Responding cells from both primary and secondary cultures were cloned by limiting
dilution procedures. For the primary cloning, cells were seeded at 16, 8, 4, 2, 1, and 0.5
cells per well in round-bottomed microwells containing 2 X 104 irradiated PBMC from
the original responder donor and 2 X 109 LCL from the original stimulator in 40 Al final
volume. For the secondarycloning, 10, 5, 2.5, 1 .2, 0.6, and0.3 cells perwell were seeded.
The cloning culture medium consisted of RPMI 1640 complemented with 2 MM L-
glutamine, 50 IU/ml penicillin, 50 Ag/ml streptomycin (all from Flow Laboratories, Inc.),
10% heat-inactivated pooled human serum from A+AB male donors, and 20 U/ml lectin-
free IL-2 (Cellular Products Inc., Buffalo, NY). 7 d after cloning, all wells were restim-
ulated with the same number of feeder cells and stimulators in a volume of 20 Al. After
10-14 d of incubation, 150 Al of complete medium were added to all proliferating clones
from wells seeded with a number of cells that resulted in <_63% growing wells. A
prescreening for cytotoxicity ofthese clones against theoriginal stimulator wasperformed.
Cytotoxic clones were further expanded by seeding 1-2 X 104 cloned cells in round-
bottomed wells containing 2-4 X 104 irradiated autologous PBMC and 2-4 X 109
irradiated LCL in a volume of 100 Al of cloning medium . 3 d later, 100 Al of cloning
medium was added. The clones were restimulated once a week. Subcloning was carried
out by limiting dilution of these clones exactly as described above.
Monoclonal Antibodies. The following mAbs were used: W6/32 (anti-HLA class I
monomorphic determinant, reference 17) was a gift ofJ. L. Strominger, Harvard Univer-
sity, Boston, MA; ME1 (anti-HLA-B27 + B7 + B22, reference 18) was a gift from A.
McMichael, Oxford University, Oxford, United Kingdom; EDU-I (anti-HLA class II
monomorphic determinant, reference 19) was a gift from R. Vilella, Hospital Clinico,
Barcelona, Spain; L243 (anti-HLA-DR monomorphic determinant, reference 20), Genox
3.53 (anti-HLA-DQw1, reference 21) and B7.21 (anti-HLA-DP monomorphic determi-
nant, reference 22) were kindly provided by C. Navarrete, from The London Hospital
Medical College, London, United Kingdom; SPV-T3b (anti-CD3, reference 23), HP2/6
(anti-CD4, reference 24), and B9/4 (anti-CD8, reference 25), were provided by F. Sanchez-
Madrid, Hospital de la Princesa, Madrid, Spain .
'Abbreviations used in this paper:
￿
LCL, lymphoblastoid cell lines; MLC, mixed lymphocyte culture;
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FACS Analysis .
￿
Phenotyping of T cells was carried out by antibody binding followed
by FACS analysis . T cell clones were cultured without feeder cells for a period of 10 d,
after which 105 cells were incubated with 50 pl of the anti-CD3, -CD4, or -CD8 hybridoma
supernatants and were stained with FITC-conjugated goat F(ab') 2 anti-mouse IgG (Kal-
lestad Laboratories, Inc ., Austin, TX) at a final dilution of 1 :50 . FACS analysis was
performed in an EPICS-C flow cytometer (Coulter Electronics Inc ., Hialeah, FL) measur-
ing the surface immunofluorescence of 5 X 10' viable cells .
Preparation of Target Cells for Cytotoxicity Assays .
￿
LCL were fed 24 h before 5 X 105
cells were labeled with 50 ,uCi of - 'Cr (Amersham Corp ., Amersham, United Kingdom)
for 1 h at 37°C in 100 /el FCS, with frequent stirring. The cells were then washed four
times with warmed RPM1 1640 medium supplemented with 5% FCS . After resuspending
in 2 ml of the same medium, the cells were counted and the radioactivity was measured
in 50 tcl of the cell suspension . They were then diluted to a concentration of 2-6 X 10"
cells/ml, allowing a minimum of 800 cpm for a volume of 50 Al of target cell suspension .
A minimum of 103 target cells were used for "Cr-release assays .
"Cr-release Cytotoxicity Assay.
￿
CTL assays were performed in V-bottomed microtiter
plates (Sterilin Ltd ., Edtham, United Kingdom) according to a modification ofa previously
described method (16) . Target cells (1-2 X 103 "Cr-labeled LCL) were incubated with
varying amounts of effector cells for 4 h at 37°C in a total volume of 150 tal . After
centrifugation (5 min at 120 X g), 100-p1 samples of cell-free supernatants were collected
and their radioactivity was measured in a Packard Instrument Co ., Inc . (Downers Grove,
IL) gamma-counter . The percentage of specific "Cr-release (SR) was calculated as follows :
SR = 100 X [(E - C)/(T - C)] where E is the cpm released by the target cells incubated
with the effectors, C is the cpm released by the target cells incubated with medium alone,
and T is the total cpm released by the target cells incubated with 100 Jul of 0.1 M HCI .
The C value was never >33% of the T value . The same procedure was used for
prescreening of the clones as well as for testing of the subclones, except that 50-Ul samples
of the microwell-growing cell suspensions containing an unknown number of effector cells
were incubated with 2 X 10 3 "Cr-labeled target cells in a final volume of 150 U1 .
Inhibition of Cytotoxicity by mAbs .
￿
This was performed as described above, except that
target (for anti-HLA mAbs) or effector (for anti-CD mAbs) cells were incubated with
varying dilutions ofthe relevant mAb for 30 min atroom temperature before the cytolytic
assay, which was then carried out at a single E/T ratio . Anti-HLA mAbs were used at
either 1 :225 dilution of ascites fluid (W6/32, ME1, and EDU-1) or at 1 :3 dilution of
hybridoma supernatant (L243, Genox 3.53 and 137.21) .
Cold-Target Inhibition Assay.
￿
Inhibition of cytotoxicity with unlabeled target cells was
carried out as above except that varying amounts of the appropriate unlabeled cells were
mixed with the "Cr-labeled targets before the addition ofeffector cells .
The percentage of inhibition (I) by both mAbs and cold target cells was calculated as
follows : 1 = 100 -[(% lysis in the presence of inhibitor)/(% lysis in the absence ofinhibitor))
X 100 .
Results
Isolation of CTL Clones.
￿
PBMC from donor PA (HLA-A24,33 ; 1335,39 ;
DRw6, DRw52 ; DQw 1) and LCL LG 15 (HLA-A32 ; 1327.1 ; DR 1 ; Dw l) were
used respectively as responder and stimulator in primary and secondary MLC .
The cells were cloned in the presence of LG15 in the primary cloning . For the
secondary cloning, LCL R69 (HLA-A3,24 ; 137,27 .1 ; DR3,5) was used as a
stimulator cell . Limiting dilutions for both primary and secondary cloning fitted
a linear regression line with r = 0.99 . After prescreening for cytotoxicity against
the original stimulator, positive clones were tested for anti-1327 activity by using
mAb ME1 for cytotoxicity inhibition assays . 55 putative clones with apparent
anti-1327 activity by these criteria were tested against a panel of LCL expressing
three different HLA-1327 subtypes : LG15 (1327 .1), R34 (1327.2), and Wewak IAPARICIO ET AL .
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(1327 .3) . Three of these clones (47, 23, and 27) were selected for their unusual
pattern of reactivity since they lysed target cells LG15 and Wewak I, whereas
R34 was not lysed . A fourth one, CTL 12, showed the same pattern of reactivity
but was later excluded on the basis of subcloning and cold-target inhibition data
that demonstrated the existence of an extra anti-HLA-137 activity consistent with
the presence oftwo separate clones in this CTL .
Clone 47 was obtained from those seeded at 1 cell per well in the primary
cloning; clones 23 and 27 came from wells seeded with 0.3 cells in the secondary
cloning. FACS analysis showed that clones 47, 23, and 27 have a homogeneous
CD3+ , CD8+ , CD4- phenotype . All three clones were able to grow with similar
efficiency when cultured in the presence of either LG15 or Wewak I as feeder
cells for 1 mo . In both situations, the clones maintained an identical pattern of
cytotoxicity against LG 15, R34, and Wewak I target cells . No proliferation in
the absence ofexogenous IL-2 was observed in any of these clones using a panel
of several stimulator LCL, including LG15 andWewak I (data not shown) . Upon
subcloning, the same pattern of lysis was observed in all subclones obtained from
clones 47, 23, and 27 (Table 1) .
Specificity ofCTL Clones 47, 23, and 27: Panel Testing.
￿
The specificity of these
clones was tested with a panel of target cells including HLA-typed LCL, PHA-
stimulated blasts, and the K562 cell line (Table II). The optimal E/T ratio for
all three clones was determined with LG15 andWewak I in dose-response assays .
These ratios were then used for all experiments and are also given in Table II .
Clones 47, 23, and 27 efficiently lysed 1327.1 targets and were negative against
1327 .2, B27f, or 1327.4 cells. This 1327.1 specificity was confirmed by using PHA-
stimulated blasts from 1327 .1 + PBMC as targets, although the lysis of these blasts
was less efficient than that of 1327.1 LCL.
The panel data confirm the cytotoxicity of these clones against Wewak I . This
cell line was more efficiently lysed than 1327.1 targets . However, its lysis is not
consistent with a 1327.1/1127 .3 crossreactivity since no significant lysis of other
1327.3 target cells (SIA and ET) was observed .A reactivity against the other class
I antigens of Wewak I (HLA-A11, A24, and Bw62) can probably be excluded
since the clones did not lyse other target cells expressing these antigens (Table
II) . Clones 47, 23, and 27 lack non-MHC-directed cytotoxicity as assessed by
negative lysis against K562 . In addition, no cytotoxicity was observed against
most 1327.1- targets, with the exception of six DR2 homozygous target cells .
Within these cells, DR2/Dw2 targets were killed with much less efficiency than
those expressing the Dw specificities DB9 or 1859 (26, 27). Those DR2+ cells
that were DR2/Dw 12 homozygous or DR2 heterozygous were not lysed . This
reactivity could be responsible forthe lysis ofWewak I, which is DR2homozygous
and whose Dw specificity is as yet not determined .
Inhibition of Cytotoxicity by Anti-HLA mAbs .
￿
To further analyze the specificity
of these clones, the ability of several anti-HLA mAbs to inhibit the lysis of a
panel of target cells was tested . Fig . 1 shows that the lysis of the LG 15 cells
(1327 .1) was inhibited by mAbs W6/32, (anti-HLA class I monomorphic deter-
minant) and ME1 (anti-HLA-1327 + B7 + Bw22). This lysis was not inhibited by
mAb EDU-1 (anti-HLA class II monomorphic determinant) . In contrast, the
cytotoxicity against Wewak I was not inhibited by the two anti-class I mAbs but432 DUAL RECOGNITION OF HLA-B27 AND HLA-DR2 BY T CELL CLONES
TABLE I
Cytotoxicity ofCTL 47, 23, and 27 Subclones
Limiting dilutions for each clone fitted linear regression lines with r values as indicated.
* C is the number of cells seeded per well that gave a plating efficiency of 63% . E/T ratio for each
subclone was unknown (see methods) . For HLA typing of target cells, see Table II .
it was inhibited by EDU-1 . Furthermore, the lysis of 12w9, PGF, and FJO (all
DR2+ targets) was also inhibited by EDU-1 and not by W6/32 . These data
confirm the apparent class 11-associated specificity of these clones, additional to
their anti-B27 .1 specificity .
To clarify the nature of the anti-class 11 specificity of clones 47, 23, and 27,
mAbs against HLA-DR, -DQ, and -DP molecules were used to inhibit the lysis
Clone
number r value C* Cells/well Subclone
number
Percent
LG15
specific lysis
R69
of target cell
Wewak I
47 0 .93 34 12 1 26 20
2 25 15
3 8 8
6 4 38 31
5 11 5
6 21 17
7 13 18
3 8 21 9
9 23 12
23 0.99 22 20 1 79 77
2 58 100
3 41 95
4 58 100
5 51 81
6 69 84
10 7 39 94
8 52 100
9 43 100
10 66 98
11 72 100
12 61 100
13 28 74
5 14 45 100
1 .2 15 45 60
16 5 13
27 0.96 9 12 1 39 40
2 46 48
3 37 32
4 39 29
5 50 59
6 52 44
6 7 27 18
8 25 19
9 37 32
10 29 26
11 12 13
1 .5 12 52 61APARICIO ET AL.
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HLA Specificity of Clones 47, 23, and 27: Panel Study
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* Results are expressedas percent mean lysis from N experiments. E:T ratios were 10:1, 0.3:1 and
0.3 :1 forclones #47, 23 and 27 respectively with all targetsexcept R15 forwhichdouble ratios were
used. ND = Not done.
$ We, Wewak.
§Spontaneous 5'Crrelease (C)was38-40% of themaximum release(T)forthis cell line. SeeMaterials
and Methods.
I No HLA expressed.
Target cell
A B
HLA
Cw DR Dw DQw 47 N
Clones*
23 N 27 N
LG15 32 27.1 2 1 1 - 29 5 44 6 48 7
R69 3,24 7,27.1 - 3,5 - - ND - 39 2 53 3
LG2 2 27.1 - 1 1 - 72 1 65 1 67 2
R15 3 35,27.1 - - - - 85 1 77 1 ND -
PHAblasts 2,11 35,27.1 1,4 1 - - 13 3 17 3 21 3
R34 2,24 18,27.2 - - - - 2 2 2 2 6 4
CHR 2,3 35,27.2 2, 4 1,5 - - ND - 0 1 1 2
R56 2,11 14,27.2 - - - - 0 1 0 1 0 1
LH 24 8, 27f 1,7 3,4 - - 4 1 0 3 2 3
We It 11,24 62,27.3 2,4 2 - - 77 5 65 6 78 8
SIA 2,24 60,27.3 4 3,5 - - 0 1 7 4 10 6
ET 2, 11 38,27.3 - 4 - - 1 1 0 1 2 1
PAR 11,24 60,27.4 - 2,11 - - 7 2 4 2 1 2
LIE§ 2, 11 5,27.4 - 12 - - 6 1 3 3 4 2
HOM1 3 7 7 2 2 1 13 1 30 1 43 1
PGF 3 7 7 2 2 1 26 2 19 3 33 2
BBF 1 37 - 2 2 1 22 1 12 4 14 4
KT7 11,24 52 - 2 12 1 0 1 0 2 0 1
TOK 24 52 - 2 12 1 0 1 2 2 1 1
12w9 2,26 57, 8w66 6 2 1859 - 94 1 68 3 75 1
FJO 2,3 7,16 - 2 DB9 1 73 2 68 3 75 1
BAS 2 51 - 2 DB9 3 61 1 58 1 83 1
AHA 2,3 7,57 6 2,7 2, 11 1, 3 1 1 0 1 1 1
CHA 2,3 7, 57 6 2,7 2, 11 1,3 0 1 0 2 2 1
We 111 11,24 18,39 6 2,5 - - 2 1 3 2 4 3
JY 2 7 - 4,6 - - 0 1 0 2 2 2
MEIN 1,3 7,57 6,7 6,7 - - 0 1 0 1 0 2
S 24,31 18,60 3 4,5 - - ND - ND - 0 1
LB 28 60 3 6 - - 0 1 2 2 8 2
B8N 3,9 8, 15 3 3,8 - - 0 1 0 1 2 2
MCF 2 62 3 4 4 3 5 1 1 1 6 2
SWEIG 29 40 2 5 - - ND - 1 2 0 3
K5621 6 2 1 2 5 2434 DUAL RECOGNITION OF HLA-B27 AND HLA-DR2 BY T CELL CLONES
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FIGURE 1 .
￿
Inhibition of the cytotoxicity of clones 47, 23, and27 by mAbs W6/32 (0), ME1
(®), and EDU-1 (/). Cytotoxicity in the absence of mAbs is also shown(®) . The E/T ratio was
10:1, 0.3:1, and 0.3 :1 with clones 47, 23, and 27, respectively for all target cells except for
PGF, for which double E/T ratios were used . For complete HLA typing of LG15
(B27 .1',DR2-), Wewak I (B27.3*,DR2+),I2w9, PGF, and FJO (B27-,DR2+) seeTable II .
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FIGURE 2 .
￿
Inhibition of the cytotoxicity of clones #47, 23 and 27 by mAbs W6/32 (®),
EDU-1 (0), L243 (" ), Genox 3.53 (M) and B7.21 (®). E/T ratios were as specified in Fig. 1 .
Specific cytotoxicity of clones 47, 23, and 27 in the absence ofmAbs was 22, 22, and 36%,
respectively, for LG-15, and 69, 31, and 50%, respectively, for Wewak I .
of Wewak I. As shown in Fig . 2, only mAb L243 (anti-DR monomorphic
determinant) inhibited the cytotoxicity, whereas Genox 3.53 (anti-DQwl) and
B7 .21 (anti-HLA-DP monomorphic determinant) showed no significant effect .
The same results were obtained usingtarget cells PGFand FJO (data not shown) .
These data strongly suggest that clones 47, 23, and 27 recognize a determinant
associated with theDR2 molecule, and not a DP- or DQwI-related determinant.
Dual Reactivity of CTL Clones 47, 23, and 27 : Cold-Target Inhibition Analy-
sis . The experiments described above suggested a dual reactivity that makes
clones 47, 23, and 27 capable of recognizing a class I determinant (B27 .1) as
well as a class II-associated determinant related to DR2 . The HLA-DR2 targets
I2w9, FJO, BAS, and Wewak I were the most efficiently killed, followed by the
B27.1 targets and the DR2/Dw2 targets (Table II) . To substantiate these differ-
ences in killing abilityandto rule out the possibility that this unusual crossreaction
was due to CTL 47, 23, and 27 not being true clones, cold-target inhibition
assays were performed . Fig. 3 shows the resultsof such experiments, reciprocally
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FIGURE 3 .
￿
Cold-target inhibition analysis of the cytotoxicity of clones 47, 23, and 27 . Hot-
target cells were LG-15 (A-C) or Wewak I (D-F) . Percent of specific "Cr release in the
absence of competing cold cells was 27 (A), 53 (B), 56 (C), 80 (D), 74 (E), and 80 (F) . Effector
to hot target ratios were the same as those in Fig . 1 . Thefollowing cold target cells were used :
LG-15 (p), Wewak I (p), and B8N (O). The latter was used as negative control. For HLA
typing of these cells see Table II .
using LG15 and Wewak I as cold and hot targets : (a) the cytotoxicity against
1127 .1 (LG15) was strongly inhibited by Wewak I and not by an unrelated
(1127 .1 -, DR2-) control target . This inhibition by Wewak I was higher than that
obtained with LG15 itself; and (b) the cytotoxicity against Wewak I was inhibited
by LG 15, but at lower rate than with Wewak I itself. These results support the
previous conclusions that CTL 47, 23, and 27 are clones and that they have a
dual reactivity against 1127 .1 and DR2-associated determinants . They also con-
firm the panel data showing a greater efficiency of killing of Wewak I vs . 1127.1
targets and suggest a higher avidity of these clones for Wewak I than for LG15 .
In a similar series of experiments using clone 23 (Fig . 4), LG15 (1127.1),
Wewak I (DR2/Dw "blank"), and PGF(DR2/Dw2) were used as hot targets and
the same cells, as well as I2w9 (DR2/Dw 1859) and FJO (DR2/DwDB9), were
used as cold targets . An unrelated LCL,JY (1127-, DR2-) was used as a control.
Lysis of LG15 targets was strongly and equally blocked by Wewak 1, IM, and
FJO . Inhibition by PGF was similar to that obtained with LG15 itself and both
were lower than that observed with the other DR2 targets . Cytotoxicity against
Wewak I was slightly inhibited by LG15 and PGF and much more efficiently by
IM and FJO, at a rate as high as that observed with Wewak I itself. All 1127 .1 +
andDR2+ cold targets inhibited the lysis ofPGF. Analogous results were obtained
using clone 47 (data not shown) . These data confirm the monoclonal nature of
CTL 23 and 47, as well as the heterogeneity of the DR2-related lysis by these
clones .
Inhibition of Cytotoxicity by Antibodies against T Cell Surface Antigens: Role ofCD3
and CD8 . To investigate the role of the CD3 and CD8 molecules on this class
I/class II crossreactive cytotoxicity, inhibition assays were performed using anti-
CD3 and anti-CD8 mAbs to block the cytotoxicity of clones 47, 23, and 27 . As
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FIGURE 4 .
￿
Cold-target inhibition analysis of the cytotoxicity of clone 23 . Hot target cells
were: (A) LG-15 (1127.1*,DR2-), (B) Wewak I (1127.3*,DR2+), and (C) PGF (1127- ,
DR2/Dw2+). Percent of specific "Cr release in the absence of competing cold cells was 40,
64, and 34%, respectively . Effector to hot target ratio was 0.3:1 . The following cold target
cells were used :IM (-V-), FJO (-0-), Wewak I (-A-), PGF (-A-), LG-15 (-~--),
andJY (--"--) . The latter was used as negative control . For HLAtyping of the cell lines see
Table II .
shown in Fig. 5, the lysis of LG15 (1127 .1) was clearly inhibited by anti-CD3 and
anti-CD8 antibodies . The lysis oftwo different DR2' target cells, Wewak I and
PGF, was strongly inhibited by mAb anti-CD3 irrespective of the significant
differences in the susceptibility to lysis of these two cells. In contrast, anti-CD8
mAb not only did not inhibit such class II-directed killing but appeared to
induce an enhancement of the cytotoxicity . A putative explanation for this
enhancement could be the bridging of the effector and target cells by the anti-
CD8 antibody through its heterologous binding to the Fc receptors on the target
LCL, thus effectively increasing the avidity of the E/T interaction. This possi-
bility was not experimentally addressed, because the anti-CD8 mAb used was
IgG2b (25) and F(ab')2 fragments for this subclass cannot be obtained (28) . No
effect of the anti-CD4 mAb was observed for any of the target cells . This
antibody was used as a control to exclude the possibility that any residual CD4+
cells not detected by FACS analysis could be contributing to the lysis of DR2'
targets. These results strongly suggest that the CD8 molecule is involved in the
class I-directed but not in the class II-directed cytotoxicity of these clones .
Discussion
in the present study, the specificity of three alloreactive CTL clones raised by
stimulation of HLA-1327-, DR2- responder cells with 1127 .1 +, DR2- cells has
been analyzed . All three clones showed an identical pattern of reactivity in that
they specifically lysed target cells expressing either HLA-1127.1 or a subset of
HLA-DR2, but the lytic capacity of CTL 47 was significantly lower, possibly
reflecting less avidity for the corresponding targets . The monoclonal character
of these clones was established on the following bases: (a) they were phenotypi-
cally homogeneous CD3+, CD8+ , CD4-; (b) their specificity was homogeneous
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FIGURE 5.
￿
Inhibition of the cytotoxicity of clones 47, 23, and 27 against LG-15 (A-C),
Wewak I (D-F), or PGF (G-I) by theanti-CD3 mAb SPV-T3b (A), the anti-CD8 mAb 139/4
(*) and the anti-CD4 mAb HP2/6 (0). Inhibition of cytotoxicity by the anti-HLA mAbs
W6/32 (A), EDU-1 (p) and L243 (Q) was used as control. The specific "Cr release in the
absence of antibody (O) is also shown. For clone 47, E/T ratios were 10:1 with LG-15 and
PGF, and 5:1 with Wewak I. For clones 23 and 27, E/T ratios were 0.3:1 with LG-15 and
PGFand 0.15:1 with Wewak I. For HLA typing of target cells see Table II .
upon subcloning; and (c) HLA-1327 .1+ targets and HLA-DR2+ targets recipro-
cally inhibited each other in cold-target inhibition assays. That these clones were
alloreactive for both HLA-1327.1 and HLA-DR2, as opposed to being allo-class
II-specific, self-class I-restricted or vice versa, was clear from a number of
criteria. First, HLA-1127 .1 was absent in the responder cells and HLA-DR2 in
both the responder and the stimulator cells. Second, lysis of DR2+ targets was
accomplished independently of whether they shared class I antigens with their
effector cells. Third, lysis ofHLA-1327.1'targets by all three clones was inhibited
by anti-class I but not by anti-class II antibodies. In contrast, lysis of HLA-DR2
target cells was inhibited by anti-class II but not by anti-class I antibodies. In
addition, all three clones lysed 1327.1+, DR2- PHA-stimulated blasts, and at least
CTL 23 also lysed DR2', 1327.1- blasts (not shown), thusexcluding the possibility
ofthese clones being EBV-specific, class I or class II restricted. Taken together,
these results indicate that CTL clones 47, 23, and 27 display dual alloreactivity
for both HLA-1327 .1 and a subset of HLA-DR2.
Neither the possibility oftwo separate receptors nor that of one receptor with
two separate binding sites being expressed on these CTL clones can be excluded
from the present data. However, no examples of either situation have been
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demonstrated so far . Thus, we consider that the simplest explanation for this
dual reactivity is that the clones recognize a crossreactive determinant shared
between HLA-B27.1 and a subset of HLA-DR2 . Some experimental grounds
for this alternative are provided by findings (29-31) suggesting that both class I
and class II antigen recognition may be mediated by the same set of T cell
receptor V genes . Therefore, with the above mentioned alternatives in mind,
further discussion will be based on the assumption that each of these clones
express a single antigen receptor with a single binding site .
Some insight into the nature of the putative determinant recognized by these
CTL clones can be obtained from their highly selective pattern of reactivity for
both the HLA-B27 .1 subtype and certain HLA-DR2 antigens . Molecular analyses
of HLA-B27 antigens strongly suggest that the epitope recognized by clones 47,
23, and 27 on HLA-B27 .1 includes at least the Asp residue at position 77, since
this residue is the only one that is unique to B27.1 among all B27 subtypes whose
structure has been examined (3, 4, 32, and our unpublished results) .
The HLA-DR2 antigen displays a remarkable polymorphism that can be
detected by cellular typing and includes at least the Dw2, Dw12, FJO/DB9, and
the I2w9/1859 specificities (26, 27) . Biochemical and DNA sequence analyses
have shown that this polymorphism is associated to heterogeneity in two DR (3
chains expressed on HLA-DR2 homozygous cell lines, as well as with polymor-
phism in the a and a chains ofDQwl (33-37) . The epitope recognized by CTL
clones 47, 23, and 27 closely correlates with the DR2-associated Dw polymor-
phism, since Dw 12 targets are not recognized by these clones and since IM,
FJO/DB9, and Dw2 targets are lysed with different degrees of efficiency . The
lack of killing of HLA-DR2 heterozygous target cells (Table II) might be due to
their lower expression of DR2 . In addition, at least two of these cells were Dw2,
for which the lytic capacity of these clones is much lower . Since the DR2-directed
killing can be significantly inhibited by an anti-DR but not by an anti-DQwl
mAb, it is likely that the putative crossreactive epitope recognized by these CTL
clones is located on the DR2 ,l chains and is related to the Dw-associated
polymorphism of these polypeptides . This is further supported by the fact that
the DR2+ , DQwl - cell line BAS was killed with comparable efficiency to other
DR2+ , DQwl + targets (Table I1) .
Whatever the molecular bases for the crossreaction between HLA-B27.1 and
various DR2-associated Dw specificities, its detection suggests that some struc-
tural feature of the HLA-B27 .1 molecule may mimic a class II determinant that
is closely related or identical to those that can induce T cell proliferation . The
biological implications ofthisphenomenon are unknown . Crossreactions between
class I and class II antigens are virtually absent inHLA serology . Thus, it would
be interesting to analyze whether the type ofcrossreactivity found in CTL clones
47, 23, and 27 reflects a unique property of HLA-B27 or a more general one of
the HLA class I antigens, so that the distinction between class I and class II
determinants recognized by T cells could be somewhat les strict than for serologic
determinants .
The availability of individual CD3+,CD8+,CD4- CTL clones with simultaneous
class I- and class II-directed lytic ability allowed us to examine the role of CD8
in the lysis of targets bearing the relevant class I or class 11 molecules by theAPARICIO ET AL .
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sameCTL. The involvement of the T cell receptor complex in both the B27.1-
directed and DR2-directed killing by these clones was strongly supported by the
fact that lysis of both 827.1+ or DR2+ targets was inhibited by an anti-CD3 mAb.
In contrast, an anti-CD8 mAb selectively blocked the lysis of827.1 + targets but
not that ofDR2' targets . Furthermore, the lack of inhibition of theDR2 targets
was independent of the different lytic efficiency of these clones for targets
expressing the various DR2-associated Dw specificities . CTL clones are hetero-
geneous in their susceptibility to inhibition by anti-CD3 and anti-CD8 antibodies
(38), and this effect has been related to the avidity of the E/T interaction (16,
39, 40) . However, it is very unlikely that differences in the relative avidity of
clones 47, 23, and 27 forB27 .1 vs . DR2 targets are responsible forthedifferential
blocking of anti-CD8 because the PGF(DR2/Dw2) and LG-I5(B27 .1) cells recip-
rocally inhibited each other in cold-target inhibition experiments with similar
efficiency (Fig . 4) . Furthermore, as mentioned above, anti-CD3 mAb inhibited
both B27.1 and DR2 targets . A similar lack of inhibition by anti-CD8 (or anti-
Lyt-2,3) mAb has been observed with some CD8+ or Lyt-2,3+ anti-class II CTL
(41, 42) . Most probably, the selective inhibition of the class I-directed lysis by
clones 47, 23, and 27 reflects a different role of the CD8 molecule depending
on the MHC antigen class being recognized on the target cell .
It is generally assumed that CD8 contributes to increasing the overall avidity
of the E/T interaction either by interacting with nonpolymorphic regions of the
class I molecules (12) or by otherwise stabilizing the binding of theCTL receptor
to the corresponding antigen (39) . The differential inhibition of the class I- but
not the class II-directed cytotoxicity of clones 47, 23, and 27 by the anti-CD8
mAb is not consistent with a simple additive contribution of theCD8 interaction
with class I antigen to the avidity of the CTL for the target cell because all
targets used in this study simultaneously expressed class I and class II antigens .
The present results can be coherently interpretedby postulating that stabilization
of theT cell receptor-MHC antigen interaction by CD8 is accomplished through
the binding of this molecule to a different epitope on the same class I molecule
bound by the antigen receptor . Anti-CD8 mAbs would inhibit lysis by disrupting
this ternary complex . In this model, a physical association of the T cell receptor
and theCD8 molecule is not required in the absence of an MHC antigen on the
target cell to which both the receptor and CD8 can bind . SinceCD8 would not
bind to class II antigens, the anti-CD8 antibody would not have any disruptive
effect in the class II-directed lysis of target cells by theseCTL clones and would
not inhibit lysis in those cases . This interpretation is analogous to the role
postulated recently (43) for L3T4 to explain the behaviour oftwo unusual Lyt-
2+ , L3T4+ hapten-specific, class II MHC-restricted T cell clones, whose antigen-
induced lymphokine production was inhibited by anti-L3T4 but not by anti-Lyt-
2 antibodies .
A regulatory role in CTL triggering has been postulated for CD8 (14) . This
is not incompatible with an additional role of CD8 in stabilizing the E/T
interaction, such as the one proposed above . But an exclusive regulatory role of
CD8 appears doubtful on the basis of our results because it would mean that the
negative signal generated upon anti-CD8 antibody binding was effective only for440 DUAL RECOGNITION OF HLA-B27 AND HLA-DR2 BY T CELL CLONES
the class I-dependent lysis but not when the same clone was recognizing a class
II antigen .
In view of the complexity of the molecular events leading toCTL recognition
and lysis and the difficulties in designing experimental systems for their direct
analysis, the availability of unusualCTL clones, such as those discussed here, can
provide unique toolsfor examiningthe function of multiple cell surface molecules
involved .
Summary
HLA-B27- responder cells were stimulated in vitro with HLA-1127 . I' lympho-
blastoid cell lines, and alloreactive CTLclones were obtained by limiting dilution .
Three of these clones specifically lysed B27.1 + targets . In addition, they also
lysed homozygous DR2 targets with various degrees of efficiency, depending on
the Dw specificity of the target cell . All three clones possessed a homogeneous
CD3+,CD8+,CD4- phenotype and were also homogeneous upon subcloning .
Cold-target inhibition analyses showed mutual inhibition of B27 .1 target lysis by
DR2 targets and vice versa . Lysis of B27.1 targets was selectively inhibited by
anti-class I mAbs . In contrast, lysis of DR2 targets was inhibited only by anti-
class I Iandanti-DR monomorphic antibodies, but not by anti-class I, anti-DQw 1,
or anti-DP antibodies . The results indicate that these clones display dual recog-
nition for HLA-B27.1 and for HLA-DR2 and suggest that HLA-B27 .1 may
share at least one epitope that is closely related to some stimulatory Dw deter-
minants present on the HLA-DR2 antigens .
Lysis of both B27+ and DR' targets was inhibited by an anti-CD3 mAb. In
contrast, an anti-CD8 antibody selectively inhibited the B27- but not the DR2-
directed killing by these clones . The data support a stabilizing role of CD8
through its binding to the same class I (but not class II) molecule on the target
cell bound by theT cell antigen receptor .
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Note added in proof . Results analogous to those described in this paper have recently been
reported in the murine system (Schilham, R . Lang, R . Benner, R . Zinkernagel, and H .
Hengardner . 1986 . Studies ofan alloreactive CTL clone specific for H-2Db that crossreacts
with I-Ek .J . Immunol . 137 : 2748 .) .
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